Cover Image
市場調查報告書

軸心型脊椎關節炎:開發中產品分析

Axial Spondyloarthritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361636
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
軸心型脊椎關節炎:開發中產品分析 Axial Spondyloarthritis - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 103 Pages
簡介

本報告提供軸心型脊椎關節炎治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

軸心型脊椎關節炎概要

治療藥的開發

  • 開發中產品的概要

軸心型脊椎關節炎:企業開發中的治療藥

軸心型脊椎關節炎:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

軸心型脊椎關節炎:企業開發中的產品

軸心型脊椎關節炎的治療藥的開發企業

  • AbbVie Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Novartis AG
  • Sandoz International GmbH
  • UCB S.A.
  • Xbrane Biopharma AB

軸心型脊椎關節炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

軸心型脊椎關節炎:最近的開發平台趨勢

軸心型脊椎關節炎:暫停中的計劃

軸心型脊椎關節炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8764IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2016, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Unknown stages are 2, 5, 2 and 1 respectively.Axial Spondyloarthritis.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Axial Spondyloarthritis Overview 7
  • Therapeutics Development 8
  • Pipeline Products for Axial Spondyloarthritis - Overview 8
  • Axial Spondyloarthritis - Therapeutics under Development by Companies 9
  • Axial Spondyloarthritis - Pipeline Products Glance 10
  • Late Stage Products 10
  • Early Stage Products 11
  • Unknown Stage Products 12
  • Axial Spondyloarthritis - Products under Development by Companies 13
  • Axial Spondyloarthritis - Companies Involved in Therapeutics Development 14
  • Eli Lilly and Company 14
  • Johnson & Johnson 15
  • Novartis AG 16
  • Panacea Biotec Ltd 17
  • Sandoz International GmbH 18
  • UCB SA 19
  • Axial Spondyloarthritis - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Target 21
  • Assessment by Mechanism of Action 23
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 29
  • adalimumab biosimilar - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • adalimumab biosimilar - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • adalimumab biosimilar - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • adalimumab biosimilar - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • certolizumab pegol - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • etanercept biosimilar - Drug Profile 47
  • Product Description 47
  • Mechanism Of Action 47
  • R&D Progress 47
  • ixekizumab - Drug Profile 49
  • Product Description 49
  • Mechanism Of Action 49
  • R&D Progress 49
  • secukinumab - Drug Profile 55
  • Product Description 55
  • Mechanism Of Action 55
  • R&D Progress 55
  • ustekinumab - Drug Profile 68
  • Product Description 68
  • Mechanism Of Action 68
  • R&D Progress 68
  • Axial Spondyloarthritis - Dormant Projects 75
  • Axial Spondyloarthritis - Product Development Milestones 76
  • Featured News & Press Releases 76
  • Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting 76
  • Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS 79
  • Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016) 80
  • Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting 83
  • Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting 88
  • Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis 91
  • Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 92
  • Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study 93
  • Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis 95
  • Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting 96
  • Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting 98
  • Apr 16, 2012: UCB Announces Positive Top-Line Phase III Results Of Cimzia In Axial Spondyloarthritis And Ankylosing Spondylitis 100
  • Appendix 102
  • Methodology 102
  • Coverage 102
  • Secondary Research 102
  • Primary Research 102
  • Expert Panel Validation 102
  • Contact Us 102
  • Disclaimer 103

List of Tables

  • Number of Products under Development for Axial Spondyloarthritis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Comparative Analysis by Late Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Development, H2 2016 11
  • Comparative Analysis by Unknown Stage Development, H2 2016 12
  • Products under Development by Companies, H2 2016 13
  • Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H2 2016 14
  • Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H2 2016 15
  • Axial Spondyloarthritis - Pipeline by Novartis AG, H2 2016 16
  • Axial Spondyloarthritis - Pipeline by Panacea Biotec Ltd, H2 2016 17
  • Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H2 2016 18
  • Axial Spondyloarthritis - Pipeline by UCB SA, H2 2016 19
  • Assessment by Monotherapy Products, H2 2016 20
  • Number of Products by Stage and Target, H2 2016 22
  • Number of Products by Stage and Mechanism of Action, H2 2016 24
  • Number of Products by Stage and Route of Administration, H2 2016 26
  • Number of Products by Stage and Molecule Type, H2 2016 28
  • Axial Spondyloarthritis - Dormant Projects, H2 2016 75

List of Figures

  • Number of Products under Development for Axial Spondyloarthritis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Comparative Analysis by Late Stage Development, H2 2016 10
  • Assessment by Monotherapy Products, H2 2016 20
  • Number of Products by Targets, H2 2016 21
  • Number of Products by Stage and Targets, H2 2016 21
  • Number of Products by Mechanism of Actions, H2 2016 23
  • Number of Products by Stage and Mechanism of Actions, H2 2016 23
  • Number of Products by Routes of Administration, H2 2016 25
  • Number of Products by Stage and Routes of Administration, H2 2016 25
  • Number of Products by Molecule Types, H2 2016 27
  • Number of Products by Stage and Molecule Types, H2 2016 27
Back to Top